MOTS-c and Retatrutide are both Metabolic peptides, but they're studied for different things. In short, MOTS-c is a mitochondrial-derived peptide studied for metabolism and exercise, while Retatrutide is an investigational triple GIP/GLP-1/glucagon agonist studied for weight loss. This page compares the two side by side — what each is researched for, how mature the evidence is, and how they're typically used — so you can see where they overlap and where they differ. It's educational information only, not medical advice, and neither is a substitute for a conversation with a licensed professional.
MOTS-c vs Retatrutide at a glance
| MOTS-c | Retatrutide | |
|---|---|---|
| Category | Metabolic | Metabolic |
| In short | A mitochondrial-derived peptide studied for metabolism and exercise. | An investigational triple GIP/GLP-1/glucagon agonist studied for weight loss. |
| Researched for | Insulin sensitivity, Metabolic health, Exercise & endurance | Weight management, Blood sugar regulation, Metabolic health |
| Research status | Preclinical research; early human interest. | Phase III clinical trials — investigational, not yet approved. |
| Typically stacked with | — | — |
| Key consideration | Mostly studied in animal and cell models. Human data is emerging. | Not FDA-approved. Prescription-grade investigational compound; use only under medical supervision. |
How does MOTS-c work?
MOTS-c is a peptide encoded within mitochondrial DNA that acts as a metabolic regulator, influencing insulin sensitivity and energy homeostasis — partly through AMPK, a key cellular energy sensor. It is studied for metabolic health and exercise capacity.
How does Retatrutide work?
Retatrutide is an investigational "triple agonist" that simultaneously activates the GIP, GLP-1, and glucagon receptors. Adding glucagon-receptor activity is thought to increase energy expenditure on top of the appetite and glycemic effects of GIP/GLP-1, and early trials have shown substantial weight reduction.
MOTS-c vs Retatrutide: how to choose
Choosing between MOTS-c and Retatrutide really comes down to your specific goal — and it's a decision for you and a licensed professional, not something to settle from a web page. MOTS-c is most associated with Insulin sensitivity and Metabolic health, while Retatrutide leans toward Weight management and Blood sugar regulation. Where they overlap, the practical differences are usually in mechanism and how far the research has actually progressed. Selpho provides no dosing or protocols; if you'd like a research-backed steer for your goals, the free Peptide Advisor is a good starting point.
Frequently asked questions
Both are Metabolic peptides. MOTS-c is a mitochondrial-derived peptide studied for metabolism and exercise; Retatrutide is an investigational triple GIP/GLP-1/glucagon agonist studied for weight loss. They're most researched for Insulin sensitivity, Metabolic health (MOTS-c) and Weight management, Blood sugar regulation (Retatrutide), respectively.
There's no universal "better" — it depends on your goal, and for most of these compounds robust head-to-head human evidence doesn't exist. The right choice is one made with a licensed professional. Selpho does not rank or prescribe; it offers educational information and a research-backed advisor.
They're in the same category, and combining research compounds is something to approach only with a licensed professional, since interactions and individual context matter. Selpho provides no dosing or protocols.
MOTS-c: Preclinical research; early human interest. Retatrutide: Phase III clinical trials — investigational, not yet approved.
Not sure which fits your goals?
Describe your situation and Selpho's free AI advisor will suggest research-backed peptides — no signup needed.
Try the Peptide AdvisorThis comparison is for educational purposes only and is not medical advice, a diagnosis, or a recommendation to use any compound. It contains no dosing or purchase information. Always consult a licensed healthcare professional before considering any peptide.